Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS MICHAEL BUZBEE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1770682619
CMS profile
34816
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$13,429.98

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS MICHAEL BUZBEE

NPI 1770682619 · CMS profile ID 34816

Allopathic & Osteopathic Physicians / Internal Medicine

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770682619?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS MICHAEL BUZBEE, NPI 1770682619, CMS profile ID 34816. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770682619?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). THOMAS MICHAEL BUZBEE, NPI 1770682619, CMS profile ID 34816. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770682619?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
THOMAS MICHAEL BUZBEE, NPI 1770682619, CMS profile ID 34816, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1770682619?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $13,429.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $18.5912/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745058151 CMS
Allergan, Inc. $6.8512/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235059 CMS
Novartis Pharmaceuticals Corporation $12.5012/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725617809 CMS
Esperion Therapeutics, Inc. $14.4712/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737186649 CMS
Merck Sharp & Dohme Corporation $12.5312/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747833989 CMS
PFIZER INC. $17.3412/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743527027 CMS
Allergan, Inc. $11.5912/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235057 CMS
Amgen Inc. $11.3912/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335053 CMS
Amgen Inc. $17.0512/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335051 CMS
Merck Sharp & Dohme Corporation $17.8811/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747813743 CMS
Allergan, Inc. $9.5711/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235055 CMS
Merck Sharp & Dohme Corporation $12.7211/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747823275 CMS
Amgen Inc. $16.5011/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741448677 CMS
Merck Sharp & Dohme Corporation $3.8111/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747815625 CMS
AbbVie Inc. $11.4411/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721716045 CMS
Lilly USA, LLC $14.5911/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728669667 CMS
Astellas Pharma US Inc $13.1411/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718305431 CMS
Novo Nordisk Inc $8.6611/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745003361 CMS
Merck Sharp & Dohme Corporation $16.3110/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747786799 CMS
Novo Nordisk Inc $12.7110/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744952967 CMS
Allergan, Inc. $8.0510/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235053 CMS
Novo Nordisk Inc $14.2510/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744943927 CMS
Allergan, Inc. $6.0510/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235051 CMS
SCILEX PHARMACEUTICALS INC. $19.2210/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752404043 CMS
AbbVie Inc. $16.1710/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721716043 CMS
Amgen Inc. $5.5810/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335049 CMS
Esperion Therapeutics, Inc. $15.7210/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737186647 CMS
Allergan, Inc. $14.8710/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235049 CMS
Horizon Therapeutics plc $11.5810/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721382261 CMS
Allergan, Inc. $2.1210/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235047 CMS
Amgen Inc. $8.0010/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335047 CMS
Novo Nordisk Inc $1.5410/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744916957 CMS
Merck Sharp & Dohme Corporation $15.7910/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747786443 CMS
Amgen Inc. $19.7510/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335045 CMS
Merck Sharp & Dohme Corporation $10.2510/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747764935 CMS
Amgen Inc. $8.1109/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335043 CMS
Novo Nordisk Inc $4.2709/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744935313 CMS
Allergan, Inc. $13.9409/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235045 CMS
Amgen Inc. $3.5109/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335135 CMS
Novo Nordisk Inc $9.5509/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744926745 CMS
Allergan, Inc. $16.7109/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723235043 CMS
Novo Nordisk Inc $1.3609/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744873311 CMS
AbbVie Inc. $15.1109/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721716041 CMS
Esperion Therapeutics, Inc. $13.4209/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737186645 CMS
Merck Sharp & Dohme Corporation $17.3709/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747772865 CMS
Amarin Pharma Inc. $11.9909/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740060277 CMS
Lilly USA, LLC $11.0009/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728659777 CMS
Amgen Inc. $16.9009/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335133 CMS
Amgen Inc. $6.2109/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741335041 CMS
Merck Sharp & Dohme Corporation $12.2209/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747772029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,961.16 244
PY2020 $13,429.98 147
PY2021 $6,223.29 116
PY2022 $31,965.13 96
PY2023 $12,486.26 104
PY2024 $21,260.57 122
PY2025 $15,885.29 116

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $13,174.30 4
PY2022 Principal investigator $35,635.00 33
PY2021 Principal investigator $30,225.06 37
PY2020 Principal investigator $22,820.00 16
PY2019 Principal investigator $31,271.69 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 American Regent $1,175.00 10/17/2022 Non-covered Recipient Entity
Pnp Research, Llc
Heart_FID No dispute reported 06/30/2026 923497427
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 08/23/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287669
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 08/23/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287673
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 08/23/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287679
Principal investigator 1 American Regent $7,902.00 08/03/2022 Non-covered Recipient Entity
Pnp Research, Llc
Heart_FID No dispute reported 06/30/2026 923497055
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283091
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283097
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283105
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283111
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283117
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283121
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283127
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283133
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 07/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283139
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 06/22/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947274055
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 06/22/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947274061
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 06/22/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947274067
Principal investigator 1 Esperion Therapeutics, Inc. $1,439.00 06/22/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947274073
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 05/24/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947265557
Principal investigator 1 Esperion Therapeutics, Inc. $38.00 05/24/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947265563
Principal investigator 1 American Regent $800.00 04/20/2022 Non-covered Recipient Entity
Pnp Research, Llc
Heart_FID No dispute reported 06/30/2026 923496715
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 04/20/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947259427
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 04/20/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947259433
Principal investigator 1 Esperion Therapeutics, Inc. $38.00 04/20/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947259439
Principal investigator 1 Esperion Therapeutics, Inc. $38.00 03/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947255511
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 03/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947256643
Principal investigator 1 Esperion Therapeutics, Inc. $38.00 03/21/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947256649
Principal investigator 1 Esperion Therapeutics, Inc. $795.00 03/01/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253777
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 03/01/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253783
Principal investigator 1 Esperion Therapeutics, Inc. $38.00 03/01/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253845
Principal investigator 1 American Regent $7,902.00 01/24/2022 Non-covered Recipient Entity
Pnp Research, Llc
Heart_FID No dispute reported 06/30/2026 923497705
Principal investigator 1 Esperion Therapeutics, Inc. $795.00 01/19/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947245351
Principal investigator 1 Esperion Therapeutics, Inc. $326.00 01/19/2022 Non-covered Recipient Entity
CARETECH CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947245409